Physician profile
Evan K Newman
NPI 1205942265
$6,044.46
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,046 · 2020: $1,084 · 2021: $430 · 2022: $484.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,559.88 | 2019-2021 | |
| Amarin Pharma, INC. | $772.37 | 2019-2020 | |
| Amgen INC. | $582.48 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $520.49 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $367.27 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.60 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $267.19 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $256.07 | 2019 | |
| Allergan, INC. | $250.03 | 2020 | |
| Pfizer INC. | $232.64 | 2019-2020 | |
| Novo Nordisk INC | $203.81 | 2019-2022 | |
| Genentech USA, INC. | $150.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $144.28 | 2022 | |
| Ironwood Pharmaceuticals, INC | $125.00 | 2019 | |
| Lilly USA, LLC | $106.13 | 2019-2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $88.75 | 2019 | |
| Novartis Pharmaceuticals Corporation | $55.91 | 2021 | |
| Celgene Corporation | $17.51 | 2019 | |
| Glaxosmithkline, LLC. | $13.05 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.